Project Grant K23HL177148
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $164K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $720,399 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Colorado-Denver. The 5-year project, running from Sep 1, 2025 to May 31, 2030, will investigate the associations between maternal microbiomes, metabolomes, and cardiovascular health outcomes in a racially and ethnically diverse pregnancy cohort. Key objectives are to characterize...
- This $1,831,848 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate how early-life disruptions to gut microbiota colonization can remodel the development of lung immune and epithelial cells, contributing to chronic respiratory diseases. The research aims to identify the critical window and key microbial taxa required for establishing long-term lung homeostasis. Preliminary data indicates that...
- This $153,117 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of the recipient's independent research career as an academic hematopathology physician-scientist. The key objectives are to study hematopoietic stem and progenitor cell (HSPC) crosstalk and transplantation, with the overarching goal of improving HSPC transplantation outcomes. The award period runs from August 1, 2025 to July 31,...
- This Project Grant award, valued at $249,000.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program. The grant supports a research project at the University of Alabama at Birmingham (UAB) titled "Early Life Stress and Cardiovascular Disease Risk: Identifying the Role of Microbial Metabolites." The project aims to investigate how early life stress affects the gut microbiome and related...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $107,834 project grant to The Leland Stanford Junior University. The grant, which runs from January 21, 2025 to January 2, 2026, aims to investigate the cardiovascular impact of novel gut-hormone agonists, including semaglutide (GLP-1R), tirzepatide (GLP-1R/GIPR), and retatrutide (GLP-1R/GIPR/GCGR). The research will involve comprehensive profiling of...
- The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $126,309 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Hospital Medical Center in Cincinnati, Ohio. This 2-year research project, awarded on June 16, 2025, aims to characterize the functional role of a novel cardiac and adipose-enriched microprotein called NRAC and its involvement in lipid droplet biogenesis and lipid metabolism within the cardiovascular system. The research will...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to investigate the role of altered mitochondrial dynamics in graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation. The $758,539 award to The Leland Stanford Junior University will fund research to identify the mechanisms leading to the release of damaged mitochondria during pre-transplant conditioning, which can contribute to the initiation...
- This $2,024,340 Project Grant was awarded on August 15, 2025 by the National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports a multi-year research effort at Boston Children's Hospital to optimize outcomes for hematopoietic stem cell transplantation (HCT), an essential treatment for high-risk non-malignant and malignant hematologic diseases. The research project...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $137,219 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Illinois in Chicago. The goal of this 5-year grant is to develop the skills of Dr. Santosh L. Saraf, a mid-career hematologist and physician-scientist, to mentor the next generation of junior investigators focused on sickle cell disease (SCD)-related research. The research aims to investigate genetic factors and the role of complement...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $166,644 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of Columbia University in the City of New York on July 16, 2025. This 5-year grant will support research examining how aging and TET2 mutations affect the inflammatory response of human hematopoietic stem cells. The research aims to improve understanding of how these factors contribute to the development of blood disorders like...